Journal
JOURNAL OF PEDIATRIC ORTHOPAEDICS
Volume 41, Issue 7, Pages E555-E562Publisher
LIPPINCOTT WILLIAMS & WILKINS
DOI: 10.1097/BPO.0000000000001839
Keywords
aneurysmal bone cysts; percutaneous sclerotherapy; ABC; risk factors; pediatrics; benign tumors
Categories
Ask authors/readers for more resources
Percutaneous sclerotherapy with polidocanol is highly effective in treating primary ABC, with a success rate of 83% and low complication rate. Risk factors for treatment failure include age younger than 5, epiphyseal plate involvement, and lower leg lesions. The only complication was an immediate allergic reaction, but the patient made a full recovery after short resuscitation.
Background: Aneurysmal bone cysts (ABC) are rare benign osseous lesions that can be locally aggressive. Traditionally, curettage with or without bone grafting is the treatment of choice. Recent data suggest that percutaneous sclerotherapy is a safe alternative to surgery. We present our experience with percutaneous sclerotherapy. Primary study aims were success rate, risk factors for treatment failure, and complications. Methods: In this single-center retrospective study (January 2003 to June 2019), 70 patients were treated with percutaneous sclerotherapy for primary ABC at various skeletal sites. Median age was 11 years (range: 3 to 17 y). Median follow-up was 40 months (range 18 to 144 mo). Clinical and radiologic assessments were performed until cyst healing. Results: Successful healing was seen in 58 of 70 patients (83%) after 1 or more injections with polidocanol. In 12 patients (17%), definitive curettage was performed after previous sclerotherapy, which was considered failure of primary sclerotherapy treatment. Trends toward increased risk for >3 treatments or treatment failure included age younger than 5, epiphyseal plate involvement, and lower leg lesions. The only complication was anaphylaxis in 1 patient shortly after injection of polidocanol/contrast agent and ropivacaine, with full recovery after short resuscitation. Conclusions: Our results show that percutaneous sclerotherapy with polidocanol has high efficacy in the treatment of primary ABC, with a low complication rate. Our only complication may have been an immediate allergic reaction to polidocanol/contrast agent or ropivacaine. Trends toward increased risk for treatment failure were age younger than 5, epiphyseal plate involvement, and lower leg lesions.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available